A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas.

Yazmín Odia; Teri N. Kreisl; Dawit Aregawi; Ellen K. Innis; Howard A. Fine

doi:10.1007/s11060-015-1894-y

A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas.

Yazmín Odia
, Teri N. Kreisl
, Dawit Aregawi
, Ellen K. Innis
, Howard A. Fine

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of neuro-oncology
Volume	125
DOIs	https://doi.org/10.1007/s11060-015-1894-y
State	Published - Jan 10 2015

Disciplines

Medicine and Health Sciences
Oncology
Pathology

Access to Document

10.1007/s11060-015-1894-yLicense: Unspecified

Cite this

@article{8bf01e0521c74770801264f8a0f9d636,

title = "A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas.",

author = "Yazm{\'i}n Odia and Kreisl, \{Teri N.\} and Dawit Aregawi and Innis, \{Ellen K.\} and Fine, \{Howard A.\}",

note = "NF-kB inhibition by bortezomib enhances tamoxifen-induced apoptosis in preclinical glioma models. We conducted a single institution, phase II trial to evaluate efficacy and safety of high dose tamoxifen with bortezomib in adults with recurrent malignant gliomas. The primary endpoint was radiographic response. Concurrent enzyme inducing anticonvulsants and grade ≥2 peripheral neuropathy were exclusion criteria.",

year = "2015",

month = jan,

day = "10",

doi = "10.1007/s11060-015-1894-y",

language = "American English",

volume = "125",

journal = "Journal of neuro-oncology",

}

TY - JOUR

T1 - A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas.

AU - Odia, Yazmín

AU - Kreisl, Teri N.

AU - Aregawi, Dawit

AU - Innis, Ellen K.

AU - Fine, Howard A.

N1 - NF-kB inhibition by bortezomib enhances tamoxifen-induced apoptosis in preclinical glioma models. We conducted a single institution, phase II trial to evaluate efficacy and safety of high dose tamoxifen with bortezomib in adults with recurrent malignant gliomas. The primary endpoint was radiographic response. Concurrent enzyme inducing anticonvulsants and grade ≥2 peripheral neuropathy were exclusion criteria.

PY - 2015/1/10

Y1 - 2015/1/10

UR - https://link.springer.com/content/pdf/10.1007%2Fs11060-015-1894-y.pdf

U2 - 10.1007/s11060-015-1894-y

DO - 10.1007/s11060-015-1894-y

M3 - Article

VL - 125

JO - Journal of neuro-oncology

JF - Journal of neuro-oncology

ER -

A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas.

Disciplines

Access to Document

Other files and links

Cite this